Andraus Maristela H, Wong Anthony, Silva Ovandir A, Wada Cicília Y, Toffleto Odaly, Azevedo Cristina P, Salvadori Myriam C
ChromAnalysis SA, São Paulo-SP, 01259-000, Brazil.
J Mass Spectrom. 2004 Nov;39(11):1348-55. doi: 10.1002/jms.667.
A simple method using a one-step liquid-liquid extraction (LLE) followed by high-performance liquid chromatography (HPLC) with positive ion electrospray ionization tandem mass spectrometric (ESI-MS/MS) detection was developed for the determination of bromazepam in human plasma, using lorazepam as internal standard. The acquisition was performed in the multiple reaction monitoring mode, monitoring the transitions: m/z 316 > 182 for bromazepam and m/z 321 > 275 for lorazepam. The method was linear over the studied range (1-100 ng ml(-1)), with r(2) > 0.98, and the run time was 2.5 min. The intra- and inter-assay precisions were 2.7-14.6 and 4.1-17.3%, respectively and the intra- and inter-assay accuracies were 87-111 and 75.8-109.5%, respectively. The mean recovery was 73.7%, ranging from 64.5 to 79.7%. The limit of quantification was 1 ng ml(-1). At this concentration the mean intra- and inter-assay precisions were 14.6 and 7.1%, respectively, and the mean intra- and inter-assay accuracies were 102.5 and 104%, respectively. Bromazepam stability was evaluated and the results showed that the drug is stable in standard solution and in plasma samples under typical storage and processing conditions. The method was applied to a bioequivalence study in which 27 healthy adult volunteers (14 men) received single oral doses (6 mg) of reference and test bromazepam formulations, in an open, two-period, randomized, crossover protocol. The 90% confidence interval of the individual ratios (test formulation/reference formulation) for C(max) (peak plasma concentration), AUC(0-96) and AUC(0-inf) (area under the plasma concentration versus time curve from time zero to 96 h and to infinity, respectively) were within the range 80-125%, which supports the conclusion that the test formulation is bioequivalent to the reference formulation regarding the rate and extent of bromazepam absorption.
建立了一种简单的方法,采用一步液液萃取(LLE),随后进行高效液相色谱(HPLC),并采用正离子电喷雾电离串联质谱(ESI-MS/MS)检测,以劳拉西泮为内标物测定人血浆中的溴西泮。采集在多反应监测模式下进行,监测以下跃迁:溴西泮的m/z 316 > 182和劳拉西泮的m/z 321 > 275。该方法在所研究的范围内(1 - 100 ng ml⁻¹)呈线性,r² > 0.98,运行时间为2.5分钟。批内和批间精密度分别为2.7 - 14.6%和4.1 - 17.3%,批内和批间准确度分别为87 - 111%和75.8 - 109.5%。平均回收率为73.7%,范围为64.5%至79.7%。定量限为1 ng ml⁻¹。在此浓度下,批内和批间平均精密度分别为14.6%和7.1%,批内和批间平均准确度分别为102.5%和104%。对溴西泮的稳定性进行了评估,结果表明该药物在标准溶液和血浆样品中在典型的储存和处理条件下是稳定的。该方法应用于一项生物等效性研究,27名健康成年志愿者(14名男性)按照开放、两期、随机、交叉方案接受单次口服剂量(6 mg)的参比和受试溴西泮制剂。Cmax(血浆峰浓度)、AUC(0 - 96)和AUC(0 - inf)(血浆浓度 - 时间曲线从零到96小时及到无穷大的面积)的个体比值(受试制剂/参比制剂)的90%置信区间在80 - 125%范围内,这支持了受试制剂在溴西泮吸收速率和程度方面与参比制剂生物等效的结论。